Leerink Partnrs Issues Negative Forecast for Zoetis Earnings

Zoetis Inc. (NYSE:ZTS) – Equities research analysts at Leerink Partnrs lowered their Q1 2025 EPS estimates for shares of Zoetis in a report issued on Monday, April 21st. Leerink Partnrs analyst D. Clark now expects that the company will post earnings per share of $1.42 for the quarter, down from their prior forecast of $1.43. The consensus estimate for Zoetis’ current full-year earnings is $6.07 per share. Leerink Partnrs also issued estimates for Zoetis’ Q2 2025 earnings at $1.61 EPS, Q4 2025 earnings at $1.38 EPS, FY2025 earnings at $6.06 EPS, FY2026 earnings at $6.78 EPS, FY2027 earnings at $7.42 EPS and FY2028 earnings at $8.05 EPS.

Several other research firms have also recently issued reports on ZTS. Piper Sandler raised their price target on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research note on Thursday, February 27th. Barclays raised their target price on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. StockNews.com upgraded Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Morgan Stanley decreased their price objective on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Finally, Stifel Nicolaus dropped their target price on Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a research note on Monday, April 14th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Zoetis presently has a consensus rating of “Buy” and a consensus target price of $214.40.

Zoetis Trading Up 1.1 %

Zoetis stock opened at $152.52 on Wednesday. The stock has a 50-day moving average price of $158.96 and a 200 day moving average price of $168.86. Zoetis has a 52 week low of $139.70 and a 52 week high of $200.33. The stock has a market cap of $68.05 billion, a PE ratio of 27.88, a P/E/G ratio of 2.78 and a beta of 0.92. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.31%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio is currently 36.56%.

Insider Transactions at Zoetis

In related news, Director Willie M. Reed sold 1,210 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. This trade represents a 9.71 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,862 shares of company stock worth $312,254. 0.16% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Callahan Advisors LLC lifted its holdings in Zoetis by 90.4% in the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock worth $2,135,000 after buying an additional 6,221 shares in the last quarter. CIBC Asset Management Inc lifted its stake in shares of Zoetis by 24.1% in the fourth quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock worth $38,617,000 after acquiring an additional 46,050 shares in the last quarter. Pensionfund Sabic boosted its holdings in Zoetis by 55.6% in the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock valued at $1,825,000 after purchasing an additional 4,000 shares during the last quarter. Schroder Investment Management Group boosted its holdings in Zoetis by 2.6% in the fourth quarter. Schroder Investment Management Group now owns 245,726 shares of the company’s stock valued at $40,036,000 after purchasing an additional 6,169 shares during the last quarter. Finally, PFW Advisors LLC acquired a new stake in Zoetis during the 4th quarter valued at approximately $1,764,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.